

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology Manuscript NO: 81125 Title: Ablative Strategies for Recurrent Hepatocellular Carcinoma Provenance and peer review: Invited Manuscript; Externally peer reviewed Peer-review model: Single blind Reviewer's code: 01221925 Position: Editorial Board Academic degree: AGAF, FACS, FICS, MD, PhD Professional title: Professor Reviewer's Country/Territory: Greece Author's Country/Territory: China Manuscript submission date: 2022-10-26 Reviewer chosen by: AI Technique Reviewer accepted review: 2022-10-26 15:23

Reviewer performed review: 2022-10-31 20:55

Review time: 5 Days and 5 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	 [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous





statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This is an interesting paper. The authors provide us with a nice overview of the different types of ablation for liver tumors. Could the authors please comment on the following: 1) The authors may wish to consider the differences (if any) in the use of ablation in HCC recurrence versus primary, since this is part of the stated goal of the paper 2)The authors may also wish to discuss a comparison between other locoregional treatment modalities and ablation for recurrent HCC 3) The authors may also wish to include a discussion about the different approaches to ablation (percutaneously, open, minimally invasive)



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 81125

Title: Ablative Strategies for Recurrent Hepatocellular Carcinoma

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06418739

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2022-10-26

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-10 00:02

Reviewer performed review: 2022-11-11 06:41

Review time: 1 Day and 6 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	 [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [] Anonymous [Y] Onymous



statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The manuscript (Manuscript ID: 81125) by Lin Wang and colleagues entitled "Ablative Strategies for Recurrent Hepatocellular Carcinoma" described the various ablation treatments for recurrent HCC. The authors systematically reviewed the pros and cons of RFA, MWA, HIFU ablation, CRA, IRE, and PEI. Furthermore, this manuscript provided evidence of combination therapy including RFA/MWA+TACE and RFA+PEI, but then the authors do not present both comparisons. The authors should discuss whether RFA+TACE and RFA+PEI are the better combination therapy for 3 to 5cm lesions with liver function compensation.